Cingulate (NASDAQ:CING) reported quarterly losses of $(0.36) per share.
Hepion’s Rencofilstat Combo Shows Anti-Tumor Activity In Nonclinical Liver Cancer Study
Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced the results of a nonclinical research study showing rencofilstat (CRV431)